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Abstract: Micafungin is an echinocandin antifungal agent available for clinical use in Japan, 
Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential 
component of the fungal cell wall, micafungin exhibits potent antifungal activity against key 
pathogenic fungi, including Candida and Aspergillus species, while contributing minimal 
toxicity to mammalian cells. This activity is maintained against polyene and azole-resistant 
isolates. Pharmacokinetic and pharmacodynamic studies have demonstrated linear kinetics both 
in adults and children with concentration-dependent activity observed both in vitro and in vivo. 
Dosage escalation studies have also demonstrated that doses much higher than those currently 
recommended may be administered without serious adverse effects. Clinically, micafungin has 
been shown to be efﬁ  cacious for the treatment of invasive candidiasis and invasive aspergillosis. 
Furthermore, the clinical effectiveness of micafungin against these infections occurs without the 
drug interactions that occur with the azoles and the nephrotoxicity observed with amphotericin B 
formulations. This review will focus on the pharmacology, clinical microbiology, mechanisms 
of resistance, safety, and clinical efﬁ  cacy of micafungin in the treatment of invasive candidiasis 
and invasive aspergillosis.
Keywords: micafungin, echinocandin, Candida, Aspergillus, invasive candidiasis, invasive 
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Introduction
During the past 15 years, the number of clinically available antifungal agents has 
increased substantially. Many of these newer agents have a broader spectrum of activity 
than ﬂ  uconazole and reduced toxicities compared to amphotericin B deoxycholate. One 
reason for the increased number of available antifungal agents is the recognition that 
invasive fungal infections remain a signiﬁ  cant clinical problem. In the United States, 
Candida species are the fourth most common cause of nosocomial bloodstream infections 
(Wisplinghoff et al 2004), and are associated with signiﬁ  cant morbidity and mortality, 
with studies reporting crude mortality rates of approximately 40% (Wisplinghoff et al 
2004; Pfaller and Diekema 2007). Reports have also demonstrated increased frequency 
of non-Candida albicans species, which may have clinical consequences as some 
species such as C. krusei and C. glabrata have reduced susceptibility to ﬂ  uconazole 
and other azoles (Bodey et al 2002; Malani et al 2005; Pfaller and Diekema 2007). 
In addition to invasive candidiasis, the incidence of infections caused by Aspergillus 
species has increased over the last decade at major cancer centers and it is a major cause 
of infectious disease-related morbidity and mortality in immunocompromised patients, 
including those with hematologic malignancies, solid organ transplant recipients, and 
those undergoing hematopoietic stem cell transplantation (Baddley et al 2001; Lin et al 
2001; Marr et al 2002; Garcia-Vidal et al 2008; Marr 2008).
The development and introduction of new azoles and lipid formulations of 
amphotericin B have not fully overcome the toxicity and drug interaction limitations Infection and Drug Resistance 2008:1 64
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associated with these antifungal classes (Wiederhold and 
Lewis 2003). Recently, the echinocandins, including 
micafungin, caspofungin, and anidulafungin, have 
become available for clinical use. Echinocandins inhibit 
(1→3)-β-D-glucan synthase, limiting the production of 
(1→3)-β-D-glucan, an essential component of the fungal 
cell wall (Douglas et al 1997). This is an attractive target 
for antifungal activity as human cells lack a homologous 
enzyme, thereby avoiding signiﬁ  cant collateral toxicities 
and drug interactions associated with the azoles and 
amphotericin B. In the United States, micafungin is 
currently approved for the treatment of esophageal 
candidiasis, candidemia, acute disseminated candidiasis, 
Candida peritonitis and abscesses, and as prophylaxis 
against Candida infections in patients undergoing 
hematopoietic stell cell transplantation (Mycamine 2008). 
The purpose of this review is to discuss the pharmacology, 
clinical microbiology, mechanisms of resistance, safety, 
and clinical efﬁ  cacy of micafungin in the treatment of 
invasive candidiasis and invasive aspergillosis.
Pharmacology
Mechanism of action
(1→3)-β-D-glucans are polysaccharides that are synthesized 
by the glucan synthase complex bound to the fungal cell 
membrane. These polysaccharides are a major component 
of the fungal cell wall contributing to its shape and integrity. 
Through non-competitive inhibition of the glucan synthase 
enzyme complex, the echinocandins lead to depletion of 
(1→3)-β-D-glucan within the cell wall, resulting in osmostic 
instability and cell wall lysis (Kurtz et al 1994; Douglas 
et al 1997; Bowman et al 2002). Against Candida species, 
exposure to micafungin may result in fungicidal activity 
(Ernst et al 2002). In this setting the minimum inhibitory 
concentration (MIC), which measures reductions in visible 
growth, may be used to assess in vitro drug activity. The 
echinocandins display unique patterns of growth inhibi-
tion against ﬁ  lamentous fungi, including Aspergillus and 
Scedosporium species, due to the glucan synthase complex 
being located at the growing apical tips (Beauvais et al 2001). 
In these organisms, exposure to an echinocandin results in 
aberrant hyphal growth with an abundance of short, stubby 
branches (Watabe et al 2003; Bowman et al 2002). Thus, the 
minimum effective concentration (MEC) has been used as an 
alternative to the MIC for measuring in vitro echinocandin 
activity against ﬁ  lamentous fungi. In vitro studies have dem-
onstrated that the MEC, deﬁ  ned as the lowest concentration 
of an echinocandin resulting in abnormally branched stubby 
hyphae, is a consistent measure of in vitro echinocandin 
activity (Arikan et al 2001; Arikan et al 2003).
Clinical microbiology
Micafungin is a relatively broad-spectrum antifungal agent 
with in vitro activity against Candida and Aspergillus spe-
cies, as well as the mycelial forms of dimorphic fungi. The 
most potent activity of micafungin is against Candida, 
including non-Candida albicans species (Table 1), and 
is conserved against clinically invasive isolates resistant 
to ﬂ  uconazole (Espinel-Ingroff 2003; Ostrosky-Zeichner 
et al 2005; Messer et al 2006; Pfaller et al 2006; Pfaller 
and Diekema 2007). Micafungin and the other available 
echinocandins lack in vitro activity against Cryptococcus 
neoformans, Fusarium species, Trichosporon species, and the 
Zygomycetes (Goodman et al 2002; Espinel-Ingroff 2003; 
Heyn et al 2005; Matsue et al 2006). Against most Candida 
species, the MIC90 ranges from 0.015 to 0.5 μg/mL (Table 1). 
However, similar to anidulafungin and caspofungin, the 
potency of micafungin is reduced against C. parapsilosis, 
C. orthopsilosis, C. metapsilosis, C. guilliermondii, and C. 
lusitaniae, with MIC90 values ranging from 0.25 to 8 μg/mL 
(Tawara et al 2000; Ostrosky-Zeichner et al 2005; Pfaller 
et al 2006; Garcia-Effron et al 2008a). Although some 
patients with infections caused by these species have been 
reported to respond to echinocandin therapy, the clinical 
signiﬁ  cance of this reduced potency is unclear as clinical 
trials have not been powered to assess efﬁ  cacy against these 
species (Mora-Duarte et al 2002; Kuse et al 2007; Pappas 
et al 2007; Reboli et al 2007).
Micafungin also exhibits signiﬁ  cant in vitro activity 
against Aspergillus species, with MEC values reported to 
be 0.125 μg/mL (Table 1) (Arikan et al 2003). In contrast, 
higher values have been reported against Aspergillus species 
when the MIC endpoint has been used (Arikan et al 2003; 
Heyn et al 2005). This may reﬂ  ect the limitation of using 
the MIC endpoint as a measure of echinocandin in vitro 
activity against ﬁ  lamentous fungi. Similarly, MEC values 
of the echinocandins against Scedosporium are lower than 
the corresponding MIC values (Arikan et al 2001; Arikan 
et al 2003). The activity of this class against Scedosporium 
species is markedly reduced compared to that reported 
against Aspergillus. In addition to Candida and Aspergillus 
species, micafungin also has potent in vitro activity against 
the mycelial forms of dimorphic fungi, such as Histoplasma 
capsulatum and Blastomyces dermatitidis, but limited 
activity against the yeast morphology of these pathogens 
encountered clinically (Nakai et al 2003). This difference Infection and Drug Resistance 2008:1 65
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in potency has been attributed to the limited amount of 
(1→3)-β-D-glucan within the cell walls of the yeast forms 
(Domer 1971; Kanetsuna and Carbonell 1971; Kanetsuna 
et al 1972; Nakai et al 2003). This activity against the 
mycelial forms of dimorphic fungi has limited clinical 
relevance, as it is the yeast morphology that is associated 
with clinical disease. Indeed, data from animal models have 
demonstrated poor activity of the echinocandins against 
infections caused by dimorphic fungi (Graybill et al 1998; 
Kohler et al 2000).
Recently, the Clinical and Laboratory Standards Institute 
(CLSI) Antifungal Subcommittee has developed recommen-
dations for echinocandin susceptibility testing, including 
breakpoints for classifying Candida isolates as susceptible to 
members of this antifungal class (Pfaller et al 2008a). Brieﬂ  y, 
the CLSI-endorsed broth microdilution method for echino-
candins is similar to that for azoles. One difference is that for 
the echinocandins the visual endpoint is read after 24 hours 
of incubation as opposed to 48 hours for the azoles. Good 
correlation between clinical outcomes and the echinocandin 
breakpoint for susceptible isolates (MIC of 2 μg/mL) has 
been observed using these methods (Pfaller et al 2008b). 
Isolates with an echinocandin MIC of 2 μg/mL are 
classiﬁ  ed as non-susceptible.
A previous multi-center study has demonstrated that 
this methodology has high interlaboratory reproduc-
ibility (Odds et al 2004). Interestingly, some in vitro 
studies have reported enhanced potency of anidulafungin 
and micafungin against Candida species compared to 
caspofungin   (Ostrosky-Zeichner et al 2003; Cota et al 
2006), while others have not noted differences in potency 
among the echinocandins  (Pfaller et al 2008a). The differ-
ences in in vitro potency observed by some investigators 
have not translated into improved efﬁ  cacy in vivo. Two 
studies have reported similar efﬁ  cacy among members of 
this class in murine models of invasive fungal infections, 
including candidiasis and aspergillosis, despite the greater 
in vitro potency of anidulafungin and micafungin (Paderu 
et al 2007; Wiederhold et al 2007). In these studies, the in 
vivo activity correlated better with the in vitro potency of 
these agents when tested in the presence of human serum. 
The effect of serum on the activity of the echinocandins 
is not fully understood. One potential explanation is that 
the observed reduction in potency is due to the signiﬁ  cant 
protein binding associated with each of these agents (Andes 
et al 2008b). Although this reduction in echinocandin 
potency may be secondary to the high degree of protein 
binding, a previous study with micafungin reported that the 
activity of this echinocandin remained greater than 50-fold 
higher than the free drug concentrations predicted by the 
protein binding ratio (Mochizuki et al 2006). Thus, although 
micafungin may demonstrate enhanced in vitro potency 
compared to caspofungin against clinical isolates, this 
may not translate into enhanced clinical efﬁ  cacy. Indeed, a 
clinical trial directly comparing micafungin to caspofungin 
for the treatment of candidemia and invasive candidiasis 
Table 1 Microdilution minimum inhibitory concentration and minimum effective concentration (μg/mL) for the clinically available 
echinocandins against Candida and Aspergillus species (Tawara et al 2000; Arikan et al 2003; Espinel-Ingroff 2003; Heyn et al 2005; Ostrosky-
Zeichner et al 2005; Pfaller et al 2006; Messer et al 2006; Pfaller et al 2006; Pfaller and Diekema 2007; Garcia-Effron et al 2008a)
Species Micafungin Anidulafungin Caspofungin
MIC range MIC90 range MIC range MIC90 range MIC range MIC90 range
Candida species
C. albicans 0.01 to 8 0.01–0.5 0.01 to 8 0.01–0.5 0.01 to 8 0.12–1
C. glabrata 0.01 to 8 0.01–0.5 0.01–8 0.12–0.5 0.01 to 8 0.06–1
C. parapsilosis 0.03 to 8 1 to 8 0.01 to 8 2 to 8 0.03 to 8 1–4
C. tropicalis 0.01 to 8 0.03–2 0.03 to 8 0.06–2 0.03 to 8 0.06–1
C. krusei 0.06–4 0.12–0.25 0.01–8 0.03–1 0.12 to 4 0.25– 2
Species MEC range MEC90 range MEC range MEC90 range MEC range MEC90 range
Aspergillus species
A. fumigatus 0.007–0.125 0.015–0.125 0.06 0.06 0.06–0.125 0.125
A. terreus 0.004–0.008 0.004–0.008 0.03 0.03 0.125–2 1
A. ﬂ  avus 0.003–0.125 0.015–0.125 0.03–0.125 0.03–0.125 0.03–0.125 0.125
A. niger 0.007–0.0125 0.008–.125 0.03–0.125 0.06–0.125 0.125–2 0.125–1
Abbreviations: MEC, minimum effective concentration; MIC, minimum inhibitory concentration.Infection and Drug Resistance 2008:1 66
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demonstrated similar clinical outcomes among the various 
treatment groups (Pappas et al 2007).
Mechanisms of resistance
As the clinical use of the echinocandins continues to grow, 
reports of echinocandin failure associated with elevated 
MIC values continue to appear in the literature. Currently, 
the most established mechanism for reduced echinocandin 
susceptibility is an alteration in the glucan synthase enzyme 
complex. Genetic studies in Saccharomyces cerevisiae 
and C. albicans ﬁ  rst suggested that alterations within this 
essential component of glucan synthase cause a reduced 
afﬁ  nity of the echinocandins to this enzyme and could 
account for elevated MICs to this class of agents (Douglas 
et al 1994; Douglas et al 1997). These studies identiﬁ  ed 
several single nucleotide polymorphisms (SNPs) that may 
occur within FKS1, the gene encoding for Fks1p, a subunit 
of the glucan synthase enzyme complex that is inhibited by 
the echinocandins (Balashov et al 2006). These SNPs occur 
within two regions of FKS1, and result in single amino acid 
substitutions within highly conserved regions of Fks1p. The 
ﬁ  rst region associated with decreased echinocandin activity 
spans approximately 10 amino acids while the second 
region comprises 20 amino acids (Figure 1). Substitutions 
within these regions have been associated with increased 
echinocandin MICs in spontaneous laboratory C. albicans 
mutants and clinical isolates (Park et al 2005). These 
amino acid changes also resulted in a signiﬁ  cant increase 
in the echinocandin 50% inhibitory concentration (IC50) 
against glucan synthase activity (Douglas et al 1997). In 
C. albicans, mutations within the highly conserved hot 
spot regions of FKS1 have been reported to lead to codon 
changes F641S, S645F, S645Y, S645P, and R1361H (Park 
et al 2005; Balashov et al 2006). Similar changes have 
been reported in a number of clinical non-C. albicans 
isolates with reduced echinocandin susceptibility (Table 2) 
collected from patients who experienced clinical failure 
while receiving an echinocandin (Kahn et al 2007; Cleary 
et al 2008; Garcia-Effron et al 2008b). In C. glabrata, 
SNPs in FKS1 and FKS2 result in amino acid changes that 
confer reduced susceptibility and have been documented 
in patients failing echinocandin therapy (Cleary et al 2008; 
Thompson et al 2008). Interestingly, a recent study has 
demonstrated that the reduced potency of echinocandins 
against C. parapsilosis and the closely related species C. 
orthopsilosis and C. metopsilosisis due to a naturally occur-
ring proline-to-alanine substitution at amino acid 660 
(P660A) at the end of one of the highly conserved hot 
spot regions within Fks1p (Garcia-Effron et al 2008a). 
Other mechanisms that may result in reduced echinocandin 
susceptibility include overexpression of the Golgi protein 
Sbe2p, which is involved in cell wall component transport 
(Osherov et al 2002), up-regulation of the cell wall integ-
rity pathway (Wiederhold et al 2005), and increases in cell 
wall chitin content (Pfaller et al 1989; Stevens et al 2006; 
Cota et al 2008). The clinical signiﬁ  cance of these other 
mechanisms is unknown.
In many of the case reports detailing clinical failure 
associated with reductions in echinocandin susceptibility, 
reduced potency occurred over a prolonged period of echi-
nocandin therapy or in patients with an untreated focus of 
infection (ie, central venous catheter, prosthesis) (Pelletier 
et al 2005; Hakki et al 2006; Cleary et al 2008). In one case 
report of a patient with esophageal candidiasis who failed 
micafungin, the MIC values rose signiﬁ  cantly over 6-week 
period of therapy from a baseline value of 0.06 μg/mL 
with similar decreases in susceptibility also observed for 
anidulafungin and caspofungin (Laverdiere et al 2006). 
In some reports, the MIC values for anidulafungin and 
micafungin remained below the recently established CLSI 
breakpoint for echinocandin susceptibility, despite a caspo-
fungin MIC of 2 μg/mL, but normalized when tested in 
the presence of serum (Wiederhold et al 2007; Thompson 
et al 2008). Similar results have been demonstrated in vivo 
and correlated to in vitro susceptibility testing done in the 
presence of serum (Wiederhold et al 2007; Maki et al 2008), 
Fks1p
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Figure 1 Linear proﬁ  le of the Fks1p subunit in Candida albicans and loci containing 
amino acid substitutions associated  with reduced echinocandin susceptibility.   Adapted 
with permission from Park S, Kelly R, Kahn JN, et al. 2005. Speciﬁ  c substitutions in the 
echinocandin target Fks1p account for reduced susceptibility of rare laboratory and 
clinical Candida sp. isolates.  Antimicrob Agents Chemother, 49:3264–73, and from Balashov 
SV, Park S, Perlin DS. 2006.   Assessing resistance to the echinocandin antifungal drug 
caspofungin in Candida albicans by proﬁ  ling mutations in FKS1.  Antimicrob Agents Chemother, 
50:2058–63. Copyright © 2005 and 2006 American Society for Microbiology.Infection and Drug Resistance 2008:1 67
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suggesting that switching to a different echinocandin when 
resistance is noted for another member of this class may not 
be appropriate (Pfaller et al 2008a). Despite the publication of 
numerous case reports of echinocandin clinical failure associ-
ated with reduced in vitro susceptibility, clinical failure due 
to echinocandin resistance appears to be of limited clinical 
scope as surveillance studies have not revealed signiﬁ  cant 
changes in the activity of these agents (Pfaller et al 2006; 
Pfaller et al 2008a).
Pharmacodynamics
Micafungin demonstrates concentration-dependent activity 
against Candida and Aspergillus species in vitro and in 
preclinical animal models. Against C. albicans, C. glabrata, 
and C. krusei, micafungin demonstrated fungicidal activity in 
time-kill studies, deﬁ  ned as a 3 log10 reduction in colony-
forming units per milliliter from the starting inoculum, with 
improved activity at higher concentrations (Ernst et al 2002). 
However, against C. tropicalis, fungistatic activity was 
observed. In animal studies of invasive candidiasis, increases 
in survival and reductions in tissue fungal burden have 
been described at doses of 0.125 mg/kg (Ikeda et al 2000; 
Maesaki et al 2000; Petraitis et al 2002). Free drug area under 
the concentration curve to MIC ratios (AUC/MIC) of 10 and 
20 have been associated with stasis and a 1 log10 reduction 
in tissue fungal burden (CFU per gram of kidney tissue), 
respectively, against susceptible C. albicans and C. glabrata 
isolates in a murine model of invasive candidiasis (Andes 
et al 2008b). These values for stasis and a 1-log reduction 
in fungal burden were similar to the AUC/MIC ratios for 
anidulafungin reported by the same investigators (Andes 
et al 2008a). Because of the long half-lives achieved clini-
cally and the tolerability observed in dose escalation trials 
(Cancidas 2005; Hiemenz et al 2005; Sirohi et al 2006), 
extended-interval dosing of the echinocandins has been 
suggested as a means of overcoming the need for daily 
intravenous therapy. This strategy has been demonstrated to 
be effective in a murine model of disseminated candidiasis 
in which a single large dose of micafungin (100 mg/kg) 
effectively reduced tissue fungal burden with no evidence 
of regrowth after 7 days in mice inoculated with C. glabrata 
(Gumbo et al 2007).
In animal models of invasive aspergillosis, increasing 
doses of micafungin have been shown to improve survival 
Table 2 Amino acid sequences and nucleotide changes in susceptible and resistant isolates from various Candida species reported in 
the literature
Isolates Protein sequence Nucleotide change  Caspofungin MIC (μg/mL)
Candida albicans (Wiederhold et al 2008)
SC5314 FLTLSLRDP – 0.125
2762 SLTLSLRDP T1922C 4
53264 FLTLPLRDP T1933C 4
Candida glabrata (Thompson et al 2008; Cleary et al 2008)
7754 FFLILSLRDP – 0.25
7755 FVLILSLRDP (Hot Spot 1) T1975G 2
06-3169 FLILSLREP (Hot Spot 2) T1896G 2
Candida krusei (Kahn et al 2007)
Ck-98 FLILSIRDP – 0.25
Ck-100 CLILSIRDP T2080K 8
Candida tropicalis (Garcia-Effron et al 2008b)
ATCC 750 FLTSLRDP – 0.25
T3 FLTLS/PLRDP T1935C 4
T26 LLTLSLRDP T1923C 1
Candida parapsilosis (Codon Change) (Garcia-Effron et al 2008a)
ATCC 22019 FLTLSLRDA P660A 1.4
H4 FLTSLRDA P660A 2.24
Note: Bolded and italicized letters refer to amino acid changes within protein sequences as a result of a nucleic acid point mutation.
Abbreviation: MIC, minimum inhibitory concentration.Infection and Drug Resistance 2008:1 68
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(Ikeda et al 2000; Petraitis et al 2002; Ichiyasu et al 2006). 
However, reductions in tissue fungal burden have not 
been consistently reported with increasing doses. In fact, a 
paradoxical attenuation of of echinocandin activity at higher 
concentrations despite an inhibitory effect at lower drug 
levels has been reported both in vitro and in vivo. In Candida 
species, the attenuated activity occurs within a range of 4 to 
32 μg/mL (Ramage et al 2002; Stevens et al 2004; Wiederhold 
et al 2005), and is both echinocandin and Candida species 
speciﬁ  c. In a study of 60 Candida bloodstream isolates, the 
highest frequency of this phenomenon was observed with 
caspofungin, occurring in 90% of C. parapsilosis, 60% 
of C. albicans, 40% of C. tropicalis, and in 1 C. krusei 
isolate (Chamilos et al 2007). For anidulafungin, this 
effect was reported in 40% of C. albicans and 20% of the 
C. tropicalis isolates tested. In contrast, a paradoxical effect 
was not observed for micafungin against any C. albicans 
or C. parapsilosis isolates, but did occur in C. tropicalis 
(70%) and C. krusei (60%) isolates. Paradoxical increases 
in markers of disease burden have been reported with higher 
doses of the ecinocandins in animal models of invasive 
aspergillosis. For micafungin, an increase in serum galacto-
mannan antigenemia was reported at a dose of 2 mg/kg/day 
compared to 1 mg/kg/day reported in a neutropenic rabbit 
model of invasive pulmonary aspergillosis (Petraitis et al 
2002). In addition, the mean total lung weight of animals 
that received dosages of 2 mg/kg/day of micafungin did not 
differ from that of infected controls even though a reduction 
was reported with a lower dosage. However, higher doses of 
micafungin did result in further damage to the hyphae and 
this was associated with signiﬁ  cant reductions in pulmonary 
infarct scores. Similarly, in a murine model of central nervous 
system aspergillosis, micafungin dosages of 10 mg/kg/day 
did not result in signiﬁ  cant clearance of residual fungal 
burden as measured by colony-forming units from the sec-
ondary site of infection, the kidneys, despite a signiﬁ  cant 
reduction in animals treated with 5 mg/kg/day (Clemons et al 
2005). In contrast, a recent study comparing micafungin to 
caspofungin in a murine model of invasive pulmonary asper-
gillosis reported no increases in pulmonary fungal burden as 
measured by quantitative real-time PCR with higher doses 
of micafungin compared to a modest paradoxical effect 
observed with caspofungin (Lewis et al 2008a). Although the 
paradoxical effect has been inconsistently reported in animal 
studies, it is important to remember that this effect appears to 
be echinocandin-dependent for the speciﬁ  c species in ques-
tion for both Candida and Aspergillus species (Chamilos et al 
2007; Antachopoulos et al 2008). Where this phenomenon 
may impact therapy is with extended interval dosing of the 
echinocandins as therapy or prophylaxis against invasive 
aspergillosis. Indeed, one study reported worse survival, 
increased pulmonary fungal burden, and persistent hyphal 
clusters within the lungs as measured by histopathology in 
mice that received a single dose of micafungin 20 mg/kg as 
prophylaxis compared to a lower dose of 10 mg/kg (Lewis 
et al 2008b).
Recently, attention has focused on the immunomodulatory 
effects of the echinocandins against fungi secondary to 
the effects of these agents on (1→3)-β-D-glucan. Besides 
having an important role on fungal cell wall structure, 
(1→3)-β-D-glucan exhibits immunostimulatory properties 
secondary to recognition by the innate immune receptor 
Dectin-1 on alveolar macrophages, neutrophils, and den-
dritic cells (Brown 2006; Taylor et al 2007). This binding 
of (1→3)-β-D-glucan by Dectin-1 triggers phagocytosis, the 
release of pro-inﬂ  ammatory cytokines, and the generation of 
reactive oxygen intermediates (Brown 2006). Recent studies 
have demonstrated that echinocandin-induced morphological 
changes in hyphae of ﬁ  lamentous fungi result in increased 
cell wall exposure of (1→3)-β-D-glucan and Dectin-1 
mediated pro-inflammatory responses by macrophages 
and neutrophils (Hohl et al 2008; Lamaris et al 2008). It is 
noteworthy that this pro-inﬂ  ammatory response has been 
primarily studied upon exposure of hyphae to caspofungin. 
However, enhanced polymorphonuclear neutrophil-mediated 
damage has also been observed when A. fumigatus hyphae are 
preincubated with anidulafungin and micafungin (Lamaris 
et al 2008). Previous studies have demonstrated A. fumigatus 
hyphae that have not been exposed to an echinocandin illicit 
a Th2 mediated inﬂ  ammatory response in dendritic cells 
resulting in poor outcomes in an animal model of invasive 
aspergillosis (Bozza et al 2002; Bozza et al 2003). Further 
work in experimental models of invasive fungal infections 
using a wide range of echinocandin doses are needed to fully 
determine the clinical relevance of the immunomodulatory 
effects of these agents.
Pharmacokinetics
Micafungin has linear pharmacokinetics over a wide range 
of doses (Hebert et al 2005b; Hiemenz et al 2005). In 
healthy adult volunteers the mean peak plasma concentration 
(Cmax) and area under the concentration curve (AUC) were 
8.8 μg/mL and 125.9 μg × h/mL, respectively, following a 
single 100 mg dose (Hebert et al 2005b). In a randomized, 
double-blind dose escalation study similar pharmacokinetic 
values were observed for micafungin doses ranging from Infection and Drug Resistance 2008:1 69
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12.5 to 200 mg/day in adult patients undergoing bone marrow 
or peripheral stem cell transplantation (Hiemenz et al 2005). 
In this study, micafungin exposure was proportional to the 
dose administered with accumulation of the drug from days 
1 to 7 following linear pharmacokinetics. In adults, the 
volume of distribution of micafungin approximates that of 
the extracellular ﬂ  uid (0.26 to 0.39 L/kg) (Hebert et al 2005b; 
Heresi et al 2006). Similar to anidulafungin and caspofungin, 
micafungin is extensively protein-bound in the plasma 
(99.5%) (Mycamine 2008). The effects of protein binding 
on the activity of echinocandins are not fully understood as 
studies on the effects of protein binding on echinocandin 
activity have reported conﬂ  icting results. While one early 
study demonstrated enhanced activity of caspofungin against 
A. fumigatus in the presence of sera (Chiller et al 2000), other 
studies have reported reduced potency of members of this class 
in the presence of human sera. Mochizuki et al reported that 
the MIC of micafungin against C. albicans increased 8-fold 
in the presence of inactivated sera (Mochizuki et al 2006). 
However, the activity of micafungin was 50-fold higher than 
that predicted by the free drug concentration proﬁ  le. Another 
recent study comparing each of the three available echinocan-
dins reported a reduction in the activity of each agent with the 
addition of 50% human sera, resulting in the neutralization of 
the enhanced potency of micafungin relative to caspofungin 
both in vitro and in vivo (Paderu et al 2007).
The pharmacokinetics of micafungin have also been 
evaluated in pediatric patients. Micafungin was administered 
at doses ranging from 0.5 to 4 mg/kg/day in an open-label 
phase I study of patients with febrile neutropenia ranging 
from age 2 to 17 years (Seibel et al 2005). Similar to adults, 
Cmax and AUC values increased in a linear fashion. However, 
consistent with previous studies of antifungal agents that 
have demonstrated greater clearance and reduced exposure 
in pediatric patients compared to adolescents and adults, 
a higher clearance and volume of distribution and shorter 
half-life were observed in patients age 2 to 8 years compared 
to those 9 to 17 years old (Table 3) (Lee et al 1992; Walsh 
et al 2004; Walsh et al 2005). In neonates less than or equal 
to 40 weeks gestational age and weighing at least 1000 g, 
linear increases in Cmax and AUC values were also observed 
following single doses of 0.75, 1.5, and 3 mg/kg (Heresi 
et al 2006). Micafungin clearance was also increased in this 
group (1.7-fold higher than that of children age 2–8 years, 
and 2.6-fold higher than adolescents age 9–17 years).
Micafungin undergoes limited phase I metabolism to 
three metabolites (M1, M2, and M5). The M1 metabolite is 
formed by metabolism of the parent drug by arylsulfatase, 
and this metabolite is further degraded by cathechol-O-
methyltransferase to M2. The third metabolite, M5, is formed 
by hydroxylation of the side chain by CYP450 isoenzymes. 
However, the cumulative AUC and Cmax of these three metab-
olites have been reported to be approximately 8% and 4%, 
respectively, of the parent compound in healthy volunteers at 
steady state (Keirns et al 2007). The primary route of micafun-
gin elimination is through fecal excretion (Mycamine 2008). 
In a health volunteer study 14C-radiolabeled micafungin was 
administered as a 25 mg dose to healthy volunteers. In this 
study, 71% of micafungin clearance occurred via biliary 
elimination via the fecal route as either unchanged parent 
drug or metabolite.
Because micafungin is not cleared renally and undergoes 
limited hepatic metabolism, its pharmacokinetic parameters 
appear to be unchanged in patients with hepatic or renal 
dysfunction. In a phase I, open-label, 100 mg single-dose 
pharmacokinetic study no differences in peak plasma 
concentration, clearance, volume of distribution, or half-life 
were observed among patients with: 1) moderate hepatic 
impairment (Child-Pugh score 7–9), 2) creatinine clearance 
30 mL/min, and 3) age and gender matched healthy controls 
Table 3 Mean micafungin pharmacokinetic parameters (±SD) by different age groups and different doses in pediatric and adult patients 
(Hebert et al 2005b; Hiemenz et al 2005; Seibel et al 2005; Heresi et al 2006)
Age group Clearance (mL/h/ kg) Half-life (h) Volume distribution (L/kg)
Neonates 1000 g 38.9 (12.1) 8.3 (1.8) 0.435 (0.11)
Children 2–8 yrs 22.5 (8.6) 11.5 (2.9) 0.335 (0.16)
Adolescents 9–17 yrs 15.1 (6.3) 13.4 (3.8) 0.243 (0.07)
Adults 14.6 (3.4) 13.1 (3.0) 0.256 (0.01)
Adult PK parameters by dose Cmax (μg/mL) AUC (μg × h/mL)
50 mg 5.1 (1.0) 54 (13)
100 mg 10.1 (2.6) 115 (25)
150 mg 16.4 (16.4) 167 (167)
Abbreviations: PK, pharmacokinetic.Infection and Drug Resistance 2008:1 70
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(Hebert et al 2005b). No differences in AUC were noted 
between patients with renal dysfunction and healthy controls. 
Patients with moderate hepatic impairment did have a lower 
micafungin AUC (97.5 μg × h/mL) compared to healthy con-
trols (125.9 μg × h/mL), although this may have been due to a 
signiﬁ  cantly higher mean body weight in this group compared 
to healthy controls. Hypoalbuminemia resulting in alterations 
in protein binding may also be a potential explanation for the 
reduced micafungin AUC in patients with hepatic impairment 
due to the high protein binding of this drug. Reductions in 
albumin may increase the volume of distribution as more 
drug is able to distribute out of the bloodstream, which has 
been shown to occur for micafungin in animals with acute 
hepatic failure (Konishi et al 2005). However, no changes 
in the weight-adjusted volume of distribution were observed 
between healthy subjects and those with moderate hepatic 
impairment in the study by Hebert et al (2005b). A subsequent 
study also reported no inﬂ  uence of hypoalbuminemia on 
micafungin plasma concentrations (Nakagawa et al 2007). 
Currently, no dosage adjustments are recommended for 
patients with mild to moderate hepatic or mild, moderate, or 
severe renal impairment (Mycamine 2008).
Interestingly, a recent study has demonstrated that 
patient weight inﬂ  uences the clearance of micafungin. Using 
a population pharmacokinetic analysis with serum micafungin 
concentration data from a previous study of bone marrow 
transplant recipients, Gumbo et al identiﬁ  ed patient weight to 
be a signiﬁ  cant covariate on the serum clearance of this echi-
nocandin (Gumbo et al 2008). The clearance of micafungin 
in patients weighing 66.3 kg or greater was increased by 50% 
compared to those weighing less than this amount. Because 
increased clearance impacts the overall drug exposure, as 
measured by the AUC, and the pharmacokinetic/pharmaco-
dynamic parameter associated with the in vivo activity of 
micafungin is the AUC/MIC ratio (Gumbo et al 2007; Andes 
et al 2008b), the authors speculated that this may negatively 
affect heavier patients infected with Candida isolates with 
higher MIC values if the dose is not increased. However, it is 
unknown if this ﬁ  nding indeed has clinical implications.
Adverse effects
Micafungin is well tolerated with few drug-related adverse 
effects reported in clinical trials. No differences in safety 
proﬁ  les were observed between micafungin and ﬂ  uconazole, 
a relatively well-tolerated antifungal, in head-to-head trials 
of these two agents (van Burik et al 2004; de Wet et al 2004; 
de Wet et al 2005). Rash, chills, nausea, vomiting, diarrhea, 
headache, and injection site reactions have been the most 
commonly reported adverse events (de Wet et al 2004; 
de Wet et al 2005; Ostrosky-Zeichner et al 2005; Denning 
et al 2006). Pruritus, facial swelling, and vasodilation have 
also been reported and may be due to histamine release that 
occurs with the intravenous administration (Mycamine 2008). 
Adverse laboratory effects associated with micafungin are 
generally mild and include elevated transaminases, alkaline 
phosphatase, and serum bilirubin (van Burik et al 2004; 
de Wet et al 2005; Mycamine 2008). Overall, few patients 
enrolled in clinical trials have discontinued micafungin due 
to adverse effects related to this drug.
The excellent safety proﬁ  le, favorable pharmacokinetics, 
and concentration-dependent activity of micafungin have 
led several investigators to evaluate the safety of dosage 
escalation with this agent. In adult bone-marrow or peripheral 
stem cell transplant patients randomized to either micafungin 
or placebo for up to 4 weeks, grade 3 or higher toxicities 
thought to be related to this echinocandin were observed 
in 4 patients at dosages of 150 or 200 mg/day (Hiemenz 
et al 2005). These included atrial ﬁ  brillation, hypokalemia, 
pancreatitis, and maculopapuler rash. However, since the 
same grade 3 or higher toxicity was not observed in at least 
3 patients in the same dosage group, the criterion for the 
maximum-tolerated dose was not met. A maximum-tolerated 
dose of micafungin was also not observed in an open-label 
study of hematopoietic stem cell transplant recipients who 
received dosages of 3, 4, 6, or 8 mg/kg/day for a period of 
8 days to 4 weeks (Sirohi et al 2006). No patients developed 
grade 3 or 4 toxicities related to micafungin, and one patient 
was able to tolerate a dose of 900 mg/day. In addition, no 
signiﬁ  cant changes in transaminase levels were reported, 
and the adverse effects observed were mild to moderate 
in severity. Similarly, a maximum tolerated dose was not 
observed in neutropenic patients age 2 to 17 years, including 
autologous and allogeneic hematopoietic stem cell transplant 
recipients, who received micafungin at 0.5 to 4 mg/kg/day 
up to a maximum of 200 mg/day (Seibel et al 2005).
Drug interactions
One of the advantages of micafungin over the azole 
antifungals is that few clinically signiﬁ  cant drug interactions 
are associated with this echinocandin. Although micafungin 
appears to be a mild inhibitor of cytochrome P450 3A4 in 
vitro, this appears to be of minimal clinical signiﬁ  cance 
as no interactions have been found with the known 3A4 
inhibitors ﬂ  uconazole, voriconazole, and ritonavir or with 
the potent inducer rifampin (Hiemenz et al 2005; Keirns 
et al 2007; Mycamine 2008). Healthy volunteer studies have Infection and Drug Resistance 2008:1 71
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demonstrated increases in nifedipine AUC (18%) and Cmax 
(42%) values in the presence of steady-state micafungin 
concentrations (Sakaeda et al 2005; Mycamine 2008). 
Similarly, micafungin has been shown to increase the AUC 
of sirolimus by 21%. In addition, the AUC and Cmax of 
itraconazole may be increased with co-administration of 
micafungin (Mycamine 2008). Thus, it is recommended 
that patients receiving sirolimus, nifedipine, or itraconazole 
in combination with micafungin be monitored for signs and 
symptoms of toxicity, and that dosage reductions of these 
medications may be necessary (Mycamine 2008).
In healthy volunteers, micafungin AUC values have been 
reported to increase between 10% and 14% with concurrent 
administration of a single dose of cyclosporine (Hebert et al 
2005c). Conversely, micafungin appears to be a mild inhibitor 
of cyclosporine metabolism, resulting in a decrease in the 
oral clearance and an increase in the half-life (Hebert et al 
2005c). Although the clinical relevance of this interaction is 
unknown, careful monitoring of cyclosporine concentrations 
may be warranted as one-ﬁ  fth of the volunteers in this study 
had potentially clinically signiﬁ  cant increases in cyclosporine 
concentrations when coadministered with micafungin. 
Interestingly, no changes in tacrolimus or micafungin phar-
macokinetic parameters were observed in a similar drug 
interaction study (Hebert et al 2005a).
Clinical efﬁ  cacy
Esophageal candidiasis
The echinocandins have a useful role in the treatment of 
esophageal candidiasis, including azole-refractory infections, 
secondary to their excellent safety proﬁ  le and limited number 
of clinically significant drug interactions. Micafungin 
has been shown in clinical studies to be as effective as 
ﬂ  uconazole for the treatment of esophageal candidiasis. In 
a double-blind dose-ranging study of HIV-positive patients 
comparing different doses of micafungin to ﬂ  uconazole 
(200 mg/day), a clear dose-response was noted in patients 
randomized to micafungin 50 mg (69%), 100 mg (77%), 
or 150 mg (90%) as measured by endoscopy (de Wet et al 
2004). Interestingly, despite similar endoscopic cure rates 
and clinical responses at the end of therapy, mycological 
eradication occurred in a higher percentage of patients who 
received micafungin 100 mg compared to those randomized 
to 150 mg (78% vs 57%, respectively; p = 0.031). However, 
successful treatment, deﬁ  ned as no evidence of esophageal 
candidiasis associated plaques at the end of therapy, did not 
differ signiﬁ  cantly among patients randomized to receive 
micafungin 100 mg or 150 mg compared to ﬂ  uconazole 
(87%). Similar outcomes were reported in a second trial 
comparing micafungin (150 mg/day) to fluconazole 
(200 mg/ day) for the treatment of endoscopy conﬁ  rmed 
esophageal candidiasis (de Wet et al 2005). In this study, 
endoscopic cure at the end of therapy was similar between 
patients randomized to micafungin and ﬂ  uconazole (88% 
in both treatment groups). In each study, micafungin was 
reported to be well tolerated with rash, fever, and phlebitis 
the most commonly observed adverse effects.
Relapses following discontinuation of therapy have 
been reported in clinical trails for each member of the 
echinocandin class, raising concerns about the use of 
these agents for the treatment of esophageal candidiasis. 
In the ﬁ  rst study discussed above, relapses were reported 
in 9 patients randomized to micafungin and in none who 
received ﬂ  uconazole (de Wet et al 2004). Similarly, in the 
second study approximately 15% of patients who received 
micafungin relapsed following discontinuation of therapy 
(de Wet et al 2005). However, 11% of patients randomized to 
ﬂ  uconazole also relapsed after the end of treatment. Similar 
relapse rates have also been reported for caspofungin and 
ﬂ  uconazole during the post-treatment period (11% and 8%, 
respectively) (Villanueva et al 2002) as well as for anidu-
lafungin (35%) (Krause et al 2004). Thus, it is unknown 
if the relapses following discontinuation of treatment 
for esophageal candidiasis is a property speciﬁ  c for the 
echinocandins.
Candidemia/invasive candidiasis
A primary use of the echinocandins is for the treatment of 
invasive candidiasis. Micafungin has been evaluated for the 
treatment of patients with invasive candidiasis/candidemia in 
three clinical trials. In an open-label, noncomparative study, 
micafungin, either alone or in combination with another 
antifungal agent, was shown to be effective in patients 
with newly diagnosed or refractory candidemia (Ostrosky-
Zeichner et al 2005). The initial dose of micafungin was 
50 mg/day (1 mg/kg for patients less than 40 kg) for the 
treatment of C. albicans infections, and 100 mg per day for 
infections caused by other Candida species. Overall treatment 
success, deﬁ  ned as a complete or partial response based on 
the global assessment of clinical and mycological response 
at the end of therapy, was 76% in patients who received at 
least one dose of micafungin, and increased to 83% in patients 
who received at least ﬁ  ve doses. Response rates were similar 
among patients who received micafungin in combination 
for refractory disease (79%), alone for newly diagnosed 
candidemia (87%), or alone for refractory candidemia (76%). Infection and Drug Resistance 2008:1 72
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As this trial was a preliminary study to obtain data on the 
efﬁ  cacy of micafungin for the treatment of candidemia, 
the dose used for the treatment of infections caused by 
C. albicans (50 mg/day) was lower than in subsequent stud-
ies, where the minimum dose was 100 mg/day regardless of 
the infection.
The efﬁ  cacy of micafungin for invasive candidiasis/
candidemia has also been compared to that of liposomal 
amphotericin B. In a double-blind, non-inferiority study 
patients were randomized to receive either micafungin 
100 mg/day or liposomal amphotericin B administered as 
3 mg/kg/day (Kuse et al 2007). The majority of patients 
enrolled in this study had candidemia, and the causative 
agent of infection was frequently a non-albicans species: 
62% in micafungin patients and 59% in those randomized 
to liposomal amphotericin B. In the intent-to-treat analysis 
overall treatment success, deﬁ  ned as clinical and mycological 
response at the end of therapy, was observed in 72% of 
patients in the micafungin group and 68% of those who 
received liposomal amphotericin B. No differences were 
observed among patients infected with different Candida 
species. Similar to a previous study that compared 
caspofungin to amphotericin B deoxycholate (Mora-Duarte 
et al 2002), micafungin was better tolerated with a lower 
incidence of nephrotoxicity and infusion-related reactions 
than those observed with liposomal amphotericin B.
Results from a pediatric sub-study as part of the micafungin 
versus liposomal amphotericin B study have recently been pub-
lished (Queiroz-Telles et al 2008). In this study, micafungin 
was administered at a dose of 2 mg/kg/day and liposomal 
amphotericin B at 3 mg/kg/day. This dose of micafungin was 
used secondary to the shorter half-life and faster clearance 
observed in premature infants and young children (Seibel et al 
2005; Heresi et al 2006). Overall treatment success was similar 
between patients who received micafungin (73%) and those 
that received liposomal amphotericin B (76%). The treatment 
success rates were consistent across age groups and in patients 
who were born prematurely, and mycologic persistence at 
the end of therapy was observed in 16% of patients in both 
treatment groups. Similar to the adult study, discontinuation 
of therapy due to adverse effects was lower in the micafungin 
group compared to liposomal amphotericin B (3.8% vs 17%, 
respectively).
In the two previously described studies, as well as other 
studies that have evaluated caspofungin and anidulafungin 
for the treatment of invasive fungal infections, a member 
of another antifungal class has been used as the active 
comparator. To date, only one clinical trial has directly 
compared two echinocandins for the treatment of invasive 
fungal infections. In this double-blind, non-inferiority study, 
patients were randomized to receive either micafungin 
100 mg/day or 150 mg/day, or caspofungin, administered 
at 70 mg on the ﬁ  rst day and 50 mg/day thereafter, for 
the treatment of invasive candidiasis/candidemia (Pappas 
et al 2007). Overall success, again deﬁ  ned as a favorable 
clinical and mycological response at the end of therapy, 
was similar among the three groups with 74% of patients 
randomized to micafungin 100 mg, 70% to micafungin 
150 mg, and 71% in those who received caspofungin having 
a favorable outcome. Interestingly, a higher response rate 
was reported for the higher dose of micafungin in patients 
with infections caused by C. glabrata. However, this study 
was not sufﬁ  ciently powered to assess differences among 
Candida species. These results demonstrate that micafungin 
is as effective as caspofungin for the treatment of invasive 
candidiasis/candidemia. Similar safety profiles among 
the treatment groups were also reported. Although a clear 
dose-response was observed in an early study that compared 
micafungin to ﬂ  uconazole for the treatment of esophageal 
candidiasis, such an effect was not observed in this study as 
micafungin 100 mg/day was as effective as the higher dose of 
150 mg/day. Overall, the response rates reported in the stud-
ies that have evaluated micafungin for invasive candidiasis/
candidemia are similar to those observed for caspofungin and 
anidulafungin as well as other antifungal agents in clinical 
studies (Figure 2) (Rex et al 1994; Mora-Duarte et al 2002; 
Kullberg et al 2005; Reboli et al 2007).
Antifungal prophylaxis
Antifungal prophylaxis has been shown to reduce the inci-
dence of invasive fungal infections and in some studies to 
improve survival (Goodman et al 2002; Winston et al 2003; 
Marr et al 2004; Cornely et al 2007; Ullmann et al 2007). 
However, this strategy is often limited by the drug interac-
tions and adverse effects associated with the azoles and 
amphotericin B formulations. The echinocandins offer an 
alternative strategy as antifungal prophylaxis secondary to 
their favorable adverse effect proﬁ  le and lack of clinically 
relevant drug interactions. In a prospective, double-blind, 
multicenter study that included autologous and allogeneic 
stem cell transplant recipients, patients were randomized 
to receive either micafungin 50 mg/day (1 mg/kg for those 
weighing less than 50 kg) or ﬂ  uconazole 400 mg/day (8 mg/kg 
in those weighing less than 50 kg) (van Burik et al 2004). 
Prophylaxis was initiated in the pre-engraftment period and 
continued until approximately 5 days after engraftment or up Infection and Drug Resistance 2008:1 73
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to 42 days post-transplant. Treatment success was deﬁ  ned 
as the absence of proven, probable, or suspected systemic 
fungal infections at the end of prophylaxis and the absence 
of proven or probable systemic fungal infections at the end 
of the 4-week follow-up period. Patients randomized to 
micafungin experienced higher treatment success compared 
to those who received ﬂ  uconazole (80% vs 74%; p = 0.03). 
No difference in breakthrough candidiasis was observed 
between the two groups. Instead, this difference was primar-
ily due to fewer cases of breakthrough invasive aspergillosis 
in the micafungin group (1 patient) compared to ﬂ  uconazole 
(7 patients). Less empiric antifungal therapy was also required 
in the micafungin group compared to ﬂ  uconazole (15% vs 
21%, respectively; p = 0.024). One of the limitations of this 
study is that the median duration of prophylaxis was only 
18 days. Thus, it is unclear how effective micafungin pro-
phylaxis would be in the setting of graft-versus host disease 
and corticosteroid therapy in allogeneic stem cell transplant 
recipients, as observational studies have demonstrated an 
increased risk of invasive aspergillosis during the post-
engraftment period (Wald et al 1997).
Invasive aspergillosis
Micafungin does not currently have an indication for the treat-
ment of invasive aspergillosis and data on its use against this 
opportunistic infection are limited. In one open-label, non-
comparative study, micafungin was evaluated as primary ther-
apy or as salvage therapy in patients who had failed previous 
therapy or were intolerant of other antifungal agents (Denning 
et al 2006). Patients were initially dosed at 75 mg/day with 
dosage escalation permitted if disease progression occurred or 
if cultures remained positive. A favorable response, deﬁ  ned 
as either a complete or partial response at the end of therapy 
based on radiological, mycological, and clinical data, was 
observed in 36% of patients who received at least one dose 
of micafungin. However, disease progression was observed 
in 53% of patients during the course of treatment. Patients 
in whom neutrophil recovery occurred had a favorable 
response rate of 50% compared to only 17% in those who 
remained neutropenic. During the 6-week follow-up period, 
overall mortality was 56%, of which 59% was considered to 
be attributable to invasive aspergillosis. Overall, the results 
of micafungin monotherapy in this study (41% favorable 
response rate) are similar to those reported for caspofungin 
monotherapy in patients receiving this echinocandin as 
salvage therapy for invasive aspergillosis (45%) (Maertens 
et al 2004). In patients with refractory disease who received 
micafungin in combination with other antifungal therapy, 
response rates were less favorable (35% with a favorable 
response; 60 of 174). Responses were especially poor in 
allogeneic stem cell transplant recipients who were receiving 
salvage antifungal combination therapy (25% with a favor-
able response; 21 of 83) (Kontoyiannis et al 2008). Similarly 
low response rates have been reported for caspofungin in 
combination with other antifungal therapy for the salvage 
treatment of invasive aspergillosis (Kontoyiannis et al 2003), 
highlighting the difﬁ  culty in treating patients with refractory 
disease.
Conclusion
The echinocandins have been a welcome addition to the 
antifungal armamentarium. Major advantages of this class 
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of agents include the potent activity against Candida and 
Aspergillus species, as well as the excellent safety compared 
to amphotericn B formulations and fewer drug interactions 
than the azoles. Clinical studies have demonstrated 
micafungin to be as safe and as effective as ﬂ  uconazole 
for the treatment of esophageal candidiasis. In addition, 
micafungin is as effective as liposomal amphotericin B 
and caspofungin for the treatment of invasive candidiasis/
candidemia. Notably, fewer adverse effects were observed for 
micafungin compared to liposomal amphotericin B in both 
adults and pediatric patients. The utility of micafungin against 
invasive aspergillosis is less clear. Although potent in vitro 
activity is observed against Aspergillus species, and these 
results are supported by preclinical in vivo studies, clinical 
data supporting the use of micafungin against invasive 
aspergillosis are scarce. Thus, while micafungin appears to 
be a suitable option for the treatment of invasive candidiasis/
candidemia, further studies are needed to accurately judge 
its role in the treatment of invasive aspergillosis.
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